Visitors view exhibits at the booth of Bloomage Biotech at the second China International Consumer Products Expo (CICPE) in Haikou, south China's Hainan Province, July 26, 2022. A batch of domestic brands have attracted a lot of visitors at the expo. (Xinhua/Yang Guanyu)
BEIJING, Feb. 14 (Xinhua) -- The joint venture (JV) set up by Chinese major hyaluronic acid producer Bloomage Biotech, Japanese firms ROHTO Pharmaceutical Co., Ltd. (ROHTO) and BioMimetics Sympathies (BMS) was recognized as a key green project at the 16th China-Japan Comprehensive Forum on Energy Saving and Environmental Protection, according to Bloomage Biotech on Monday.
The joint venture, founded in July 2022, has been settled in the Haikou National High-tech Zone of south China's Hainan Province. The launch of the joint venture represents a strategic step of Bloomage Biotech to chart the territory of regenerative medicine and cell culture medium industry.
The forum is co-organized by China's National Development and Reform Commission (NDRC), Ministry of Commerce (MOC), Japan's Ministry of Economy, Trade and Industry, and the Japan-China Economic Association.
(Edited by Li Shimeng with Xinhua Silk Road, lishimeng@xinhua.org)
A single purchase
